Please login to the form below

Not currently logged in

FDA approves Pfizer’s new cancer pill

Pfizer headquarters

Drug was previously approved as an organ rejection treatment

Merck files all-oral hepatitis C therapy in US

Merck and Co - US headquartersSeeking approval for grazoprevir and elbasvir, which already has FDA breakthrough status

Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

French immuno-oncology biotech reported to be next on pharma giant's hit list

Teva hit with $1.2bn pay-for-delay fine

Teva Pharma logoFederal Trade Commission continues its tough stance against generic blocking

Novartis and Google to fund ‘robotic pill’ maker

Firms sign up to Rani Therapeutics’ new drug delivery system

Sanofi pays $245m for FDA priority review voucher

Sanofi headquartersPRV reduces review time from ten to six months

FDA approves two new IBS medicines

FDA headquarters White OakUS regulator gives the nod to Actavis’ and Salix’ bowel drugs

Express Scripts pushes for pay-for-performance in cancer

UK Life Sciences Strategy - one year onStates it is the only way to fund the growing cost of cancer care

Sanofi licenses cardiovascular therapy in South Korea

Sanofi receptionPhase III drug comes from Swedish company NeuroVive

Get Real! The Rise of Observational Data In Healthcare

Real world data is now becoming a serious research tool for pharma, but just what can it add to the golden standard that is the randomised clinical trial?

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to our world. We specialise in creating, launching and revitalising brands all over the world. We blend science, creative,...

Latest intelligence

The patient will see you now
GCI Health’s Laura Starr and Chris Bath report on how the dawning era of mobile tech and the ‘Internet of Things’ has transformed the health and wellness arena....
When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....